196 related articles for article (PubMed ID: 29496349)
41. Update on group A streptococcal vaccine development.
Dale JB; Walker MJ
Curr Opin Infect Dis; 2020 Jun; 33(3):244-250. PubMed ID: 32304470
[TBL] [Abstract][Full Text] [Related]
42. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins.
Lei B; Liu M; Chesney GL; Musser JM
J Infect Dis; 2004 Jan; 189(1):79-89. PubMed ID: 14702157
[TBL] [Abstract][Full Text] [Related]
43. Vaccination with Streptococcus pyogenes nuclease A stimulates a high antibody response but no protective immunity in a mouse model of infection.
Radcliff FJ; Fraser JD; Proft T
Med Microbiol Immunol; 2015 Apr; 204(2):185-91. PubMed ID: 25119670
[TBL] [Abstract][Full Text] [Related]
44. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
[TBL] [Abstract][Full Text] [Related]
45. Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.
McNeilly C; Cosh S; Vu T; Nichols J; Henningham A; Hofmann A; Fane A; Smeesters PR; Rush CM; Hafner LM; Ketheesan N; Sriprakash KS; McMillan DJ
PLoS One; 2016; 11(6):e0156639. PubMed ID: 27310707
[TBL] [Abstract][Full Text] [Related]
46. Group A streptococcal infections in children.
Steer AC; Danchin MH; Carapetis JR
J Paediatr Child Health; 2007 Apr; 43(4):203-13. PubMed ID: 17444820
[TBL] [Abstract][Full Text] [Related]
47. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
48. An eight-plex immunoassay for Group A streptococcus serology and vaccine development.
Whitcombe AL; Han F; McAlister SM; Kirkham LS; Young PG; Ritchie SR; Atatoa Carr P; Proft T; Moreland NJ
J Immunol Methods; 2022 Jan; 500():113194. PubMed ID: 34801540
[TBL] [Abstract][Full Text] [Related]
49. Strategies in the development of vaccines to prevent infections with group A streptococcus.
Good MF; Batzloff MR; Pandey M
Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
[TBL] [Abstract][Full Text] [Related]
50. A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases.
Moore HC; Cannon JW; Kaslow DC; Lamagni T; Bowen AC; Miller KM; Cherian T; Carapetis J; Van Beneden C
Clin Infect Dis; 2022 Sep; 75(7):1245-1254. PubMed ID: 35438130
[TBL] [Abstract][Full Text] [Related]
51. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
Ozberk V; Pandey M; Good MF
Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
[TBL] [Abstract][Full Text] [Related]
52. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.
Davies MR; McIntyre L; Mutreja A; Lacey JA; Lees JA; Towers RJ; Duchêne S; Smeesters PR; Frost HR; Price DJ; Holden MTG; David S; Giffard PM; Worthing KA; Seale AC; Berkley JA; Harris SR; Rivera-Hernandez T; Berking O; Cork AJ; Torres RSLA; Lithgow T; Strugnell RA; Bergmann R; Nitsche-Schmitz P; Chhatwal GS; Bentley SD; Fraser JD; Moreland NJ; Carapetis JR; Steer AC; Parkhill J; Saul A; Williamson DA; Currie BJ; Tong SYC; Dougan G; Walker MJ
Nat Genet; 2019 Jun; 51(6):1035-1043. PubMed ID: 31133745
[TBL] [Abstract][Full Text] [Related]
53. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
54. Progress in development of Group A Streptococcus vaccines.
Song Y; Zhang X; Lu C; Zhang F; Zhu H
Curr Pharm Biotechnol; 2013; 14(11):947-50. PubMed ID: 24372248
[TBL] [Abstract][Full Text] [Related]
55. Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.
Williamson DA; Smeesters PR; Steer AC; Morgan J; Davies M; Carter P; Upton A; Tong SY; Fraser J; Moreland NJ
BMC Infect Dis; 2016 Oct; 16(1):561. PubMed ID: 27733129
[TBL] [Abstract][Full Text] [Related]
56. [Distribution of emm genotypes and antibiotic susceptibility of Streptococcus pyogenes strains: analogy with the vaccine in development].
Arslan U; Oryaşın E; Eskin Z; Türk Dağı H; Fındık D; Tuncer I; Bozdoğan B
Mikrobiyol Bul; 2013 Apr; 47(2):318-23. PubMed ID: 23621731
[TBL] [Abstract][Full Text] [Related]
57. Progress toward a global group a streptococcal vaccine.
Steer AC; Dale JB; Carapetis JR
Pediatr Infect Dis J; 2013 Feb; 32(2):180-2. PubMed ID: 23328823
[No Abstract] [Full Text] [Related]
58. Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
Dale JB; Penfound TA; Tamboura B; Sow SO; Nataro JP; Tapia M; Kotloff KL
Vaccine; 2013 Mar; 31(12):1576-81. PubMed ID: 23375817
[TBL] [Abstract][Full Text] [Related]
59. Conserved anchorless surface proteins as group A streptococcal vaccine candidates.
Henningham A; Chiarot E; Gillen CM; Cole JN; Rohde M; Fulde M; Ramachandran V; Cork AJ; Hartas J; Magor G; Djordjevic SP; Cordwell SJ; Kobe B; Sriprakash KS; Nizet V; Chhatwal GS; Margarit IY; Batzloff MR; Walker MJ
J Mol Med (Berl); 2012 Oct; 90(10):1197-207. PubMed ID: 22527883
[TBL] [Abstract][Full Text] [Related]
60. Preventing rheumatic fever: M-protein based vaccine.
Tandon R
Indian Heart J; 2014; 66(1):64-7. PubMed ID: 24581098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
